secwatch.observer — SEC 8-K summary
======================================

Issuer:     DENTSPLY SIRONA Inc. (XRAY)
CIK:        0000818479
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0000818479-25-000018
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dentsply Sirona starts strategic review for Wellspect Healthcare unit
---------------------------------------------------------------------

- Wellspect provides bladder/bowel care products (LoFric, Navina); $2B TAM.
- Mid-to-high single-digit organic sales growth in 2023 and first 3Q of 2024.
- Goldman Sachs & Co. LLC (financial) and Wachtell Lipton (legal) retained as advisors.
- No deadline or assurance that a transaction will result from the review.
- Q4 & full-year 2024 results to be reported on February 27, 2025 as planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818479/000081847925000018/0000818479-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818479/000081847925000018/xray-20250211.htm
  HTML page:      https://secwatch.observer/filing/0000818479-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer